April 14, 2025

FDA Clears Tablet for Cholestatic Pruritus

The FDA has approved a tablet formulation of maralixibat (LIVMARLI) for treating cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.

Conexiant

April 11, 2025

FDA Clears Longest Lasting CGM

Dexcom G7 15 Day receives FDA clearance, offering adults with diabetes the longest lasting and most accurate continuous glucose monitoring system to date.

Conexiant

April 10, 2025

September Deadline for Autism Etiology Findings

Federal initiative aims to pinpoint causes of rising autism rates by September, as HHS Secretary Kennedy launches global research effort.

Reuters

April 09, 2025

Dual Immunotherapy Approved for Advanced CRC

The FDA approved nivolumab with ipilimumab for unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer.

Conexiant

April 09, 2025

22 Drugs Tied to Melasma

Researchers identified 22 drugs, primarily hormonal agents, associated with melasma.

Conexiant

April 04, 2025

State Measles Cases Up 14% in 3 Days

Measles cases have been reported in 20 U.S. jurisdictions this year.

Reuters

April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant

April 02, 2025

FDA Misses Novavax Decision Date

FDA misses April 1 deadline for deciding on Novavax's COVID-19 vaccine.

Reuters

April 02, 2025

FDA Approves Automated Latent TB Test

Revvity’s Auto-Pure 2400 platform for use with the T-SPOT.TB test to automate latent tuberculosis diagnostics was approved by the FDA.

Conexiant